摘要
目的探讨前列腺特异性抗原密度(prostate specific antigen density,PSAD)在调强适形放疗(intensity modulated conformal radiotherapy,IMRT)联合激素治疗晚期前列腺癌疗效评估中的意义。方法选取本院2007年1月至2009年10月间收治的39例晚期前列腺癌患者,在常规激素治疗基础上行IMRT。监测患者治疗前后PSAD水平,同时随访患者肿瘤的复发和转移情况。结果与治疗前相比较,37例患者PSAD显著下降(P<0.001),在治疗后3个月左右接近正常水平;在PSAD下降的患者中有9例PSAD值24个月内又有升高,其中7例经穿刺活检证实肿瘤复发或影像学检查显示新发转移灶。PS-AD对患者复发和转移的敏感度为87.50%,明显高于TPSA的30.77%,两者比较有统计学意义(P=0.04)。结论 IMRT联合激素治疗是晚期前列腺癌的有效治疗方式,PSAD可作为评定与监测疗效的敏感指标。
Objective To evaluate the significance of the efficacy assessment of prostate specific antigen density （PSAD） in intensity modulated eonformal radiotherapy （IMRT） combined with hormonotherapy treatment of advanced prostate cancer. Methods Thirty-nine patients with advanced prostate cancer in our hospital from January 2007 to October 2009 were involved. PSAD level was measured before and after IMRT treatment based on endocrine therapy. The tumor recurrence and metastasis were followed-up. Results The PSAD value were significantly decreased compared with those before treatment in 37 patients （P 〈 0.001 ）. The PSAD value of 9 patients was increased within 24 months, and 7 of those patients who had tumor recurrence and metastasis were confirmed by biopsy or imaging examination. The sensitivity of PSAD in patients with recurrence and metastasis was 87.50% which was significantly higher than TPSA （ 30.77 % , P = 0.04 ）. Conclusion IMRT treatment combined withendocrine therapy could be effective against advanced prostate cancer. PSAD could be a sensitive indicator for assessing and monitoring the therapeutic efficacy of advanced prostate cancer.
出处
《哈尔滨医科大学学报》
CAS
北大核心
2012年第6期579-581,586,共4页
Journal of Harbin Medical University
基金
哈尔滨市科委青年基金项目(005AFQXJ068)
黑龙江省卫生厅科研课题(2009047)
关键词
调强适形放射治疗
前列腺特异性抗原密度
晚期前列腺癌
intensity modulated conformal radiotherapy
prostate specific antigen density
ad-vanced prostate cancer
